Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Invested Capital (2019 - 2025)

Keros Therapeutics filings provide 7 years of Invested Capital readings, the most recent being $303.1 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 46.96% to $303.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $303.1 million, a 46.96% decrease, with the full-year FY2025 number at $303.1 million, down 46.96% from a year prior.
  • Invested Capital hit $303.1 million in Q4 2025 for Keros Therapeutics, down from $703.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $728.9 million in Q1 2025 to a low of $211.2 million in Q2 2022.
  • Median Invested Capital over the past 5 years was $314.7 million (2023), compared with a mean of $381.5 million.
  • Biggest five-year swings in Invested Capital: skyrocketed 1098.8% in 2021 and later tumbled 46.96% in 2025.
  • Keros Therapeutics' Invested Capital stood at $243.2 million in 2021, then grew by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then crashed by 46.96% to $303.1 million in 2025.
  • The last three reported values for Invested Capital were $303.1 million (Q4 2025), $703.6 million (Q3 2025), and $706.7 million (Q2 2025) per Business Quant data.